MedPath

Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Completed
Conditions
Atrial Fibrillation
Interventions
Registration Number
NCT03187197
Lead Sponsor
Boehringer Ingelheim
Brief Summary

To describe the treatment perception from patients with non-valvular atrial fibrillation (NVAF) receiving Pradaxa® or VKA for stroke prevention by using the self-estimation questionnaire of PACT-Q during a 6-month study period.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1315
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Cohort APradaxa®consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
Cohort BPradaxa®patients being newly diagnosed with NVAF and initiated on Pradaxa®
Primary Outcome Measures
NameTimeMethod
Mean PACT-Q2 Scores, for Patients in Cohort B, at Second and Last Assessment Compared Between Treatment GroupsVisit 2 (30-45 days after initiation on Pradaxa® or VKA) and Visit 3 (150-210 days after initiation on Pradaxa® or VKA).

The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores were more favorable. The two dimension scores were presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD). Propensity score matching (PSM) method was used to identify matched Pradaxa® and VKA patients. Only the matched patients in each treatment group was summarized and used for comparison.

Mean Perception of Anticoagulant Treatment Questionnaire 2 (PACT-Q2) Scores, for Patients in Cohort A, at Second and Last Assessment Compared to Baseline AssessmentBaseline, Visit 2 (30-45 days after initiation on Pradaxa®), Visit 3 (150-210 days after initiation on Pradaxa®).

The PACT-Q was a self-administered questionnaire which was developed as a means to investigate patients´ satisfaction with anticoagulant treatment and treatment convenience in patients with deep venous thrombosis (DVT), pulmonary embolism (PE) or atrial fibrillation (AF). The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). Items for convenience and for burden of disease and treatment were reversed(reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score (CDS). Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score (SDS). High scores were more favorable. The two dimension scores were presented for Baseline, Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).

Secondary Outcome Measures
NameTimeMethod
Mean PACT-Q2 Scores, for Patients in Cohort A, at Last Assessment Compared to Second AssessmentVisit 2 (30-45 days after initiation on Pradaxa®) and Visit 3 (150-210 days after initiation on Pradaxa®).

The PACT-Q2 was composed of three dimensions covering: convenience (11 items), burden of disease and treatment (2 items), and anticoagulant treatment satisfaction (7 items). The PACT-Q2 was to be administered to patients once treatment was ongoing. Items for convenience and for burden of disease and treatment were reversed (reversed score = 6 - item score), added together and rescaled on a 0-100 scale to obtain the convenience dimension score. Items for anticoagulant treatment satisfaction were summed and rescaled on a 0-100 scale to determine the satisfaction dimension score. High scores were more favorable. The two dimension scores were presented for Visit 2 (second assessment) and Visit 3 (last assessment) as mean and standard deviation (SD).

Description of PACT-Q1 Items for Patients in Cohort B at BaselineBaseline

The PACT-Q1 was composed of a single dimension (7 items), covering the expectations of patients regarding their anticoagulant treatment, and was to be administered before treatment initiation. The 7 items were: Q1: How confident are you that your anticoagulant treatment will prevent blood clots? Q2: Do you expect that your anticoagulant treatment will relieve some of the symptoms you experience? Q3: Do you expect that your anticoagulant treatment will cause side effects such as minor bruises or bleeding? Q4: How important is it for you to have an anticoagulant treatment that is easy to take? Q5: How concerned are you about making mistakes when taking your anticoagulant treatment? Q6: How important is it for you to take care of your anticoagulant treatment by yourself? Q7: How concerned are you about how much you pay for your anticoagulant treatment? Responses ranged from 1 (Not at all) to 5 (Extremely/Completely/Very much).

Trial Locations

Locations (24)

China Medical University Hospital

🇨🇳

Taichung, Taiwan

Mackay Memorial Hospital

🇨🇳

Taipei, Taiwan

Show Chwan Memorial Hospital

🇨🇳

Changhua, Taiwan

National Taiwan University Hospital-Hsin-Chu Branch

🇨🇳

Hsinchu, Taiwan

Chang Gung Memorial Hospital(TaoYuan)

🇨🇳

Taoyuan, Taiwan

Shin Kong International HealthCare Center

🇨🇳

Taipei, Taiwan

Chia-Yi Christian Hospital

🇨🇳

Chia-Yi City, Taiwan

Chang-Hua Christian Hospital

🇨🇳

Changhua, Taiwan

Hsinchu MacKay Memorial Hospital

🇨🇳

Hsinchu, Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

E-Da Hospital

🇨🇳

Kaohsiung, Taiwan

Far Eastern Memorial Hospital

🇨🇳

New Taipei City, Taiwan

Kaohsiung Chang Gung Memorial Hospital

🇨🇳

Kaohsiung, Taiwan

Taipei Medical University-Shuang Ho Hospital

🇨🇳

New Taipei City, Taiwan

Taichung Veterans General Hospital

🇨🇳

Taichung, Taiwan

NCKUH

🇨🇳

Tainan, Taiwan

Chi Mei Medical Center

🇨🇳

Tainan, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Tainan Municipal An-Nan Hospital

🇨🇳

Tainan, Taiwan

Taipe Veterans General Hospital

🇨🇳

Taipei City, Taiwan

Taipei Medical University Hospital

🇨🇳

Taipei City, Taiwan

Tri-Service General Hospital

🇨🇳

Taipei, Taiwan

National Taiwan University Hospital Yun-Lin Branch

🇨🇳

Yunlin County, Taiwan

Taipei Municipal Wanfang Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath